Quadriga Biosciences
- Biotech or pharma, therapeutic R&D
Quadriga's lead clinical program QBS72S is an small molecule targeted to LAT1 with exceptional single agent activity in animal models, a completed Phase 1 human trial and two ongoing Phase 2 trials: frontline GBM and TNBC with brain metastases.
Address
Los AltosCalifornia
United States
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}